Validating the ABCD-GENE Score to Identify Stable Coronary Artery Disease Patients Undergoing Elective PCI at Risk of Heart Injury During Procedure

What this Trial Is About

Researchers are evaluating the ability of the ABCD-GENE score, a precision medicine tool combining clinical and genetic factors, to identify stable coronary artery disease CAD patients undergoing elective percutaneous coronary intervention PCI who are at risk of peri-PCI myocardial infarction or myocardial injury. These complications occur in up to 30% of patients despite newer stents and are linked to worse outcomes. The study aims to prospectively validate this score in patients treated with standard clopidogrel therapy. This study is a prospective cohort involving about 500 stable CAD patients receiving elective PCI and standard care clopidogrel. Participants are divided into two groups based on their ABCD-GENE score, which includes age, body mass index, chronic kidney disease, diabetes, and a genetic marker CYP2C19 loss of function. Platelet reactivity and high platelet reactivity status are assessed after PCI using the VerifyNow P2Y12 test. Additionally, high sensitivity troponin levels are measured post-PCI to detect myocardial infarction or injury. Participants will undergo blood tests after PCI to measure platelet reactivity and troponin levels to determine myocardial infarction or injury within 24 hours. The study closely monitors these outcomes to validate the predictive accuracy of the ABCD-GENE score. The research may help tailor antiplatelet treatment strategies for patients at increased risk. The trial is expected to continue through August 2027.

A Precision Medicine Approach to Identify Patients Undergoing Elective PCI at Risk of Peri-PCI Myocardial Infarction